Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Alzinova

1.84 SEK

+10.34 %

Less than 1K followers

ALZ

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
+10.34 %
+24.90 %
+31.14 %
+8.77 %
-46.94 %
-52.92 %
-10.05 %
-63.61 %
-74.40 %

Alzinova is a biotechnology company. The company specializes in the therapeutic treatment of Alzheimer's and conducts research and development of peptides that are further developed as vaccines. In addition, the company also develops various research tools within the field of work. The largest operations are found in the Nordic market. The company was founded in 2011 and has its headquarters in Mölndal.

Read more
Market cap
191.54M SEK
Turnover
5.71M SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
26/2
2026

Annual report '25

All
Press releases
3rd party
ShowingAll content types
Press release15 hours ago

DNB Carnegie Access: Alzinova: Memorandum of Understanding for commercial partnership in Saudi Arabia

Alzinova
Regulatory press release18 hours ago

Alzinova ingår avsiktsförklaring för kommersiellt partnerskap

Alzinova
Regulatory press release18 hours ago

Alzinova enters memorandum of understanding for commercial partnership

Alzinova

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release11/13/2025, 5:24 PM

Redeye: Alzinova (Q3 review) - Regulatory progress in anticipation of a deal

Alzinova
Press release11/13/2025, 5:18 PM

DNB Carnegie Access: Alzinova: Progress hinges on partnership execution – Q3 review

Alzinova
Press release11/13/2025, 1:07 PM

BioStock: FDA-godkännande och starka data positionerar Alzinova inför fas II

Alzinova
Press release11/13/2025, 1:07 PM

BioStock: FDA approval and strong data position Alzinova ahead of Phase II

Alzinova
Regulatory press release11/13/2025, 6:45 AM

Alzinova offentliggör delårsrapport för januari – september 2025

Alzinova
Regulatory press release11/13/2025, 6:45 AM

Alzinova publishes interim report for January – September 2025

Alzinova
Press release11/11/2025, 1:39 PM

Alzinova deltar vid CTAD 2025 med två presentationer om ALZ-101

Alzinova
Press release11/11/2025, 1:39 PM

Alzinova to participate at CTAD 2025 with two presentations on ALZ-101

Alzinova
Press release10/20/2025, 8:23 AM

BioStock: Alzinova säkrar kortsiktig finansiering – vd kommenterar

Alzinova
Press release10/20/2025, 8:23 AM

BioStock: Alzinova secures short-term financing – CEO comments

Alzinova
Press release10/16/2025, 8:49 AM

DNB Carnegie Access: Alzinova: Secures short-term loan

Alzinova
Regulatory press release10/15/2025, 9:48 PM

Alzinova ingår kortfristigt låneavtal om 11 miljoner kronor för att säkra rörelsekapitalbehovet

Alzinova
Regulatory press release10/15/2025, 9:48 PM

Alzinova enters into SEK 11 million short-term loan arrangement to secure its working capital needs

Alzinova
Press release10/7/2025, 8:01 AM

BioStock: Alzinova kommenterar Fast Track från FDA

Alzinova
Press release10/7/2025, 8:01 AM

BioStock: Alzinova comments on the FDA Fast Track Designation

Alzinova
Press release10/6/2025, 6:38 AM

DNB Carnegie Access: Alzinova: FDA clears ALZ-101 for Fast Track

Alzinova
Regulatory press release10/4/2025, 8:45 AM

Alzinova får Fast Track-status från amerikanska läkemedelsmyndigheten (FDA) för ALZ-101 mot Alzheimers sjukdom

Alzinova
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.